Takeda Pharmaceutical Company Limited ADR (TAK)
NYSE: TAKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TAK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $69.55B
- P/E (TTM)
- 311.00
- Forward P/E
- 41.08
- EPS (TTM)
- $0.07
- Dividend yield
- 927.88% ($202.00)
- Ex-dividend date
- Mar 31, 2025
- 52-week range
- 14.16 – 22.07
- Day range
- 21.74 – 22.07
- Volume / Avg
- 3.80M / 2.73M
- Beta
- —
- Shares outstanding
- 3.19B
- Next earnings
- Jan 28, 2027
52-week range
TAK stock today
Takeda Pharmaceutical (TAK) closed at $21.77 on Nov 20, up 1.68% (+$0.36), versus the S&P 500's 3.70% decline. At this level, TAK sits near the top of its 52-week range of $14.16 to $22.07: 1.4% below the high, set on Nov 20, 2026 and 53.7% above the low. TAK is up 39.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.2%.
At 311.0x trailing earnings, Takeda Pharmaceutical trades above the peer-group median of 43.2x. Its forward P/E of 41.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Takeda Pharmaceutical's next earnings report is expected on Jan 28, 2027. Takeda Pharmaceutical pays an annual dividend of $202.00 per share, a 927.88% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Takeda Pharmaceutical
Company profileTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Julie Kim
- Headquarters
- Chuo
- Employees
- 47,029
- IPO year
- 2018
- Website
- takeda.com
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$24.53+12.68%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Jan 28, 2027
- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $0.44 vs $0.31
- Surprise
- +41.94%
Dividends
Dividend history- Annual dividend
- $202.00
- Dividend yield
- 927.88%
- Last payment
- $0.339
- Ex-dividend date
- Mar 31, 2025
TAK news
All TAK news- Takeda Pharmaceutical's ORZEYFUL Is Now Available In US For Narcolepsy Type 1 TreatmentNasdaqTAK, BIO.B
- ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?NasdaqADMA, GRFS, TAK
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthNasdaqHRMY, TGTX, TAK, TARS
- DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?NasdaqDNLI, BIIB, TAK
- Friday's ETF Movers: PPH, PSINasdaqAZN, TAK, INTC, TSEM
- Takeda Pharmaceutical's Earnings Growth Has Yet To Translate To Higher Cash FlowSeeking Alpha
- What Takeda Pharmaceutical (TAK) Said on Its Q2 Earnings CallNasdaq
- Takeda Pharmaceutical Company Limited 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
Takeda Pharmaceutical peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TEVATeva Pharmaceutical Industries Limited | 39.23 | +1.79% | $45.77B | vs TAK |
| ONCBeOne Medicines Ltd. ADR | 390.94 | -2.19% | $44.66B | vs TAK |
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs TAK |
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs TAK |
| RPRXRoyalty Pharma plc Class A | 68.45 | +1.08% | $39.36B | vs TAK |
| ZTSZoetis Inc. Class A | 79.11 | -2.08% | $32.14B | vs TAK |
| GMABGenmab A/S ADS | 50.60 | -1.46% | $31.20B | vs TAK |
| INSMInsmed Incorporated | 141.33 | -2.17% | $31.01B | vs TAK |
Indexes, lists and sector
Takeda Pharmaceutical stock FAQ
What is Takeda Pharmaceutical's stock price today?
TAK last traded at $21.77 as of Nov 20, 4:00 PM EST, up 1.68% on the day. Prices are delayed at least 15 minutes.
Does Takeda Pharmaceutical pay a dividend?
Yes. Takeda Pharmaceutical pays $202.00 per share annually, a 927.88% yield. The most recent dividend of $0.339 had an ex-dividend date of Mar 31, 2025.
When is Takeda Pharmaceutical's next earnings date?
Takeda Pharmaceutical is expected to report earnings on Thursday, January 28, 2027.
What is TAK's P/E ratio?
TAK trades at a trailing P/E ratio of 311.00 and a forward P/E of 41.08, compared with a median of 43.2 for its closest peers.
Who is Takeda Pharmaceutical's CEO?
Ms. Julie Kim is the chief executive officer of Takeda Pharmaceutical Company Limited ADR, which has about 47,029 employees.
What is the TAK 52-week high?
The 52-week high for TAK is $22.07 and the 52-week low is $14.16. The stock is currently 1.4% below its high.